UPLIFT on track to complete enrollment Q3 2022, UP-NEXT to initiate in Q2 2022, and UPGRADE on track for 2H 2022 interim data readout
XMT-1660 and XMT-2056 expected to enter clinic mid-2022
Research collaboration and license agreement with Janssen leverages Mersana’s ADC expertise and Dolasynthen platform
Strengthened financial position with $40 million upfront payment from Janssen, $45.6 million in proceeds from strategic use of ATM with participation from long-term investors, and up to $100 million from line of credit
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.